a MassBiologics of the University of Massachusetts Medical School , Boston , MA , USA.
b MassBiologics of the University of Massachusetts Medical School , Boston , MA , USA.
Hum Vaccin Immunother. 2017 Nov 2;13(11):2738-2741. doi: 10.1080/21645515.2017.1362516. Epub 2017 Sep 21.
There is a global shortage of equine-derived diphtheria anti-toxin (DAT) for diphtheria treatment. There are few existing data on serum antibody concentrations and neutralizing activity post-treatment to support development of new therapeutics. Antibody concentrations were quantified by ELISA and anti-toxin neutralizing activity by cytotoxicity assay in serum from 4 patients receiving DAT for suspected diphtheria. Using linear mixed effects modeling, estimated mean (SE) half-life was 78.2 (20.0) hours. Maximum serum neutralizing activity ranged from 28.42-38.64 AU/mL with an estimated mean AUC of 1396.7 (399.3) AU/mL*hr. These data provide a standard of comparison for development of novel anti-toxins to replace DAT.
目前全球用于治疗白喉的马源抗毒素(DAT)短缺。关于治疗后血清抗体浓度和中和活性的数据很少,难以支持新疗法的开发。通过 ELISA 定量检测了 4 例疑似白喉患者接受 DAT 治疗后的血清抗体浓度,通过细胞毒性测定法检测了 DAT 的中和活性。通过线性混合效应模型,估计平均(SE)半衰期为 78.2(20.0)小时。最大血清中和活性范围为 28.42-38.64 AU/mL,估计 AUC 平均值为 1396.7(399.3)AU/mL*hr。这些数据为开发替代 DAT 的新型抗毒素提供了比较标准。